Medication therapy management involves using clinical pharmacists to review a patient’s use of prescription medications, over-the-counter products and supplements to evaluate potential therapy problems and maximize the effectiveness of treatment. Because research has indicated that not only does MTM improve quality, but it can lead to significant cost savings, CMS has required that Part D plans, including Medicare Advantage plans which have Part D coverage, identify certain classes of beneficiaries who could benefit from MTM and do an outreach to engage those patients in a comprehensive evaluation of their drug therapies. But a new analysis from Avalere finds that many beneficiaries are not getting the benefit of MTM. (Avalere Analysis) Avalere says that about 25% of beneficiaries are eligible for an MTM intervention, but only 11% received any kind of review. In looking at the top ten Part D carriers, MTM enrollment varied from 4.6% to 17.5%, but the actually receipt of a comprehensive medication review was between 2% and 74% of the enrolled beneficiaries. Overall, a very small 1% of Part D enrollees received a CMR, much lower than the number who could likely have benefited from one. Medicare Advantage plans did a better job, with enrollees in those being three times more likely to get a CMR and many of those had an actual intervention to improve care, such as a call to a prescriber or a change in therapy. Part of the reason for the low use of MTM is that beneficiaries have to agree to participate and many don’t want to or don’t understand the potential benefit. CMS could help by providing incentives for participation. But Part D sponsors have little incentive to encourage MTM, as it is not currently a STAR measure. They get some pressure from CMS, but until there are some teeth in the program, the plan sponsors won’t likely really make an effort to use MTM.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Cano Health apparently cannot, as it declares bankruptcy due to too much debt. Building primary care centers to serve Medicare, Medicaid and commercial populations, which is Cano’s business, was hot...
February 6, 2024
Turquoise health raises a fresh $30 million in capital for its price transparency platform, as the market for funding health care companies isn’t quite dead yet.
January 24, 2024
I am co-f0under of a company that manages cell and gene therapy for health plans. Cell therapy has made a big difference for many cancer patients but like all new...
January 24, 2024
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace